as 05-30-2025 4:00pm EST
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | WAYNE |
Market Cap: | 253.2M | IPO Year: | N/A |
Target Price: | $46.29 | AVG Volume (30 days): | 52.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -5.05 | EPS Growth: | N/A |
52 Week Low/High: | $11.17 - $29.27 | Next Earning Date: | 05-15-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
PVLA Breaking Stock News: Dive into PVLA Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
GuruFocus.com
16 days ago
GlobeNewswire
17 days ago
GlobeNewswire
24 days ago
GlobeNewswire
a month ago
Insider Monkey
a month ago
Simply Wall St.
a month ago
GlobeNewswire
a month ago
The information presented on this page, "PVLA Palvella Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.